Tyrosine kinase inhibitors (TKIs) targeting EGFR were used as the first-line treatment for patients with metastatic NSCLC whose tumors harbor EGFR mutations 5; however, those patients eventually develop acquired resistance through either secondary EGFR mutations, e.g., T790M, or activation of the bypass track signaling pathways, such as activation of RTK AXL to maintain persistent oncogenic EGFR signaling 6. This evidence concerns the gene EGFR and non-small cell lung carcinoma.